Morningstar Investment Management LLC Sells 18,590 Shares of Intuitive Surgical, Inc. $ISRG

Morningstar Investment Management LLC reduced its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 63.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,817 shares of the medical equipment provider’s stock after selling 18,590 shares during the quarter. Morningstar Investment Management LLC’s holdings in Intuitive Surgical were worth $6,126,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Glenview Trust Co increased its holdings in Intuitive Surgical by 1.9% in the fourth quarter. Glenview Trust Co now owns 116,662 shares of the medical equipment provider’s stock worth $66,073,000 after purchasing an additional 2,222 shares in the last quarter. Genus Capital Management Inc. bought a new stake in Intuitive Surgical in the fourth quarter worth approximately $228,000. HBK Sorce Advisory LLC increased its holdings in Intuitive Surgical by 5.8% in the fourth quarter. HBK Sorce Advisory LLC now owns 3,967 shares of the medical equipment provider’s stock worth $2,247,000 after purchasing an additional 219 shares in the last quarter. Allen Capital Group LLC increased its holdings in Intuitive Surgical by 15.3% in the fourth quarter. Allen Capital Group LLC now owns 1,254 shares of the medical equipment provider’s stock worth $710,000 after purchasing an additional 166 shares in the last quarter. Finally, Hantz Financial Services Inc. increased its holdings in Intuitive Surgical by 105.6% in the fourth quarter. Hantz Financial Services Inc. now owns 31,772 shares of the medical equipment provider’s stock worth $17,994,000 after purchasing an additional 16,322 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive unveiled more than 100 upcoming upgrades for its da Vinci 5 robotic surgery system, including improved force-feedback tools, telecollaboration features, and security/reliability enhancements, which could strengthen the company’s competitive moat and support future procedure growth. Intuitive Surgical’s Da Vinci 5 Upgrades Aim To Deepen Moat For Investors
• Positive Sentiment: Intuitive also announced innovations tied to its “Quintuple Aim” strategy, reinforcing product development momentum and the company’s push to improve surgeon autonomy and operating-room efficiency. Intuitive Announces Innovations to Advance Quintuple Aim
• Positive Sentiment: Wall Street commentary remains moderately optimistic, with analysts still bullish on Intuitive Surgical’s long-term prospects despite recent underperformance versus the broader market. Are Wall Street Analysts Bullish on Intuitive Surgical Stock?
• Neutral Sentiment: Investor interest continues around the SP platform, where strong procedure growth suggests an important future opportunity, but it remains unclear whether this is true addressable-market expansion or mostly a shift within existing robotic procedures. ISRG’s SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
• Neutral Sentiment: There was also minor insider selling by an executive, but the transactions were very small and made under a pre-arranged 10b5-1 plan, so the signal for investors is limited. Mark Brosius insider transaction
• Negative Sentiment: The stock has also been hurt by recent weakness after earnings, with market commentary noting a roughly 7% decline since the last report, reflecting concern that the shares may need more proof of sustained acceleration. Why Is Intuitive Surgical (ISRG) Down 7.2% Since Last Earnings Report?
• Negative Sentiment: Several articles also point out that ISRG has significantly lagged the market over the past six months, which may be keeping valuation-sensitive investors on the sidelines. 3 Big Reasons ISRG Should Be On Your Watchlist

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Gary Loeb sold 400 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $446.95, for a total transaction of $178,780.00. Following the completion of the sale, the executive vice president owned 6,120 shares in the company, valued at approximately $2,735,334. This represents a 6.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Myriam Curet sold 105 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $493.95, for a total value of $51,864.75. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 5,701 shares of company stock valued at $2,783,807 in the last three months. Insiders own 0.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ISRG shares. TD Cowen lowered their target price on Intuitive Surgical from $660.00 to $585.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Piper Sandler decreased their price objective on Intuitive Surgical from $620.00 to $580.00 and set an “overweight” rating for the company in a report on Wednesday, April 22nd. Barclays set a $651.00 price objective on Intuitive Surgical and gave the company an “overweight” rating in a report on Thursday, April 23rd. Raymond James Financial decreased their price objective on Intuitive Surgical from $615.00 to $577.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Finally, UBS Group decreased their price objective on Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Nineteen equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $579.33.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $438.10 on Monday. The company has a market cap of $155.16 billion, a price-to-earnings ratio of 53.10, a P/E/G ratio of 3.50 and a beta of 1.51. Intuitive Surgical, Inc. has a 52 week low of $417.74 and a 52 week high of $603.88. The business has a 50 day moving average price of $458.62 and a 200-day moving average price of $510.37.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, beating the consensus estimate of $2.08 by $0.42. The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.62 billion. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The company’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.81 earnings per share. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.